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Despite improvements in treatment regimens for osteosarcoma (OS) patients, survival rate has not increased over the last two
decades. New treatment modalities are therefore warranted. Preclinical results with conditionally replicative adenoviruses (CRAds)
to treat OS are promising. One type of CRAd that was effective against OS cells is Ad5-D24RGD. In other types of cancer, CRAds
have been shown to interact synergistically with chemotherapeutic agents. Chemotherapy for OS often includes doxorubicin and
cisplatin. Therefore, we explored combination treatment of OS cell lines and primary OS cell cultures with Ad5-D24RGD and
doxorubicin or cisplatin. On OS cell lines, combination treatment was additive to synergistic. Surprisingly, however, on seven of eight
primary OS samples no such combination effects were observed. In contrast, in many cases chemotherapy even inhibited CRAd-
mediated cell killing. The inhibitory effect of doxorubicin on Ad5-D24RGD in primary OS cells appeared to correlate with slow cell
growth rate; reduced viral replication and absence of chemotherapy-induced G2 cell cycle arrest. Our results point to the possibility
that, at least for OS, virotherapy and chemotherapy should best not be performed simultaneously. In general, our work underscores
the importance of testing new genetic anticancer agents and treatment regimens on primary cancer specimens.
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Osteosarcoma (OS) is the most common primary bone tumour.
Patients are treated with an aggressive chemotherapy regimen
before and after surgery. Improvement of chemotherapeutic drug
regimens and surgical techniques resulted in an overall event-free
survival rate of approximately 50–70% (Link et al, 1986; Bacci et al,
2001; Bielack et al, 2002). Patients with local recurrence after
chemotherapy or overt metastatic disease have a much poorer
outcome. Recent trials indicate that 5-year survival rate has reached
a plateau, with little or no improvement by conventional treatment
modalities (Link et al, 1986; Bacci et al, 2001; Bielack et al, 2002).
New treatment modalities for OS are therefore warranted.
Conditionally replicative adenoviruses (CRAds) represent a
potential new treatment modality for solid tumours including OS
(Alemany et al, 2000; Hemminki et al, 2003). Conditionally
replicative adenoviruses are developed to selectively replicate in
tumour cells thereby causing specific tumour cell lysis. Released
virus from lysed cells can subsequently infect neighbouring
tumour cells, which results in lateral propagation of CRAds.
Previously, we demonstrated that the CRAd Ad5-D24RGD (Suzuki
et al, 2001) shows antitumour efficacy against primary OS cells in
vitro and in vivo (Witlox et al, 2004).
To assess the value of a new treatment modality, it is useful to
investigate its efficacy in combination with conventional anti-
cancer agents that constitute standard therapy. This is particularly
relevant for clinical development, where patients are usually not
withheld from conventional treatment. Conventional chemother-
apy for OS often includes cisplatin and doxorubicin. A synergistic
antitumour effect of CRAds with doxorubicin or cisplatin has been
reported previously for other types of cancer (Heise et al, 1997;
You et al, 2000; Li et al, 2001; Portella et al, 2002) and CRAd
therapy combined with chemotherapy has already shown promis-
ing results in solid tumours in phase I and II clinical trials (Khuri
et al, 2000; Lamont et al, 2000; Reid et al, 2001). Therefore, we
sought to determine a possible future role of Ad5-D24RGD in
combination with doxorubicin or cisplatin for OS treatment, by
testing this combination treatment first on OS cell lines and
subsequently on a panel of short-term cultured primary OS cells.
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Cell lines and primary OS cells
The OS cell lines MG-63, SaOs-2 and U2OS were kindly provided
by Dr C Lo ¨wik (Leiden University Medical Center, The Nether-
lands), Dr F van Valen (Westfalische Wilhelms-Universitat
Mu ¨nster, Germany) and Dr S Lens (Dutch Cancer Institute,
Amsterdam, The Netherlands), respectively, and were maintained
in F12-supplemented Dulbecco’s Modified Eagle Medium (DMEM-
F12) with 10% fetal calf serum (FCS) and 50IUml
 1 penicillin plus
50mgml
 1 streptomycin (PS) (Life technologies, Breda, The
Netherlands) at 371C in a humidified, 5% carbon dioxide
atmosphere.
Eight primary and fresh OS tumour samples were retrieved from
three patients before chemotherapy treatment was started (OS-6, 8
and 16), from one patient after chemotherapy (OS-5A), and from
two patients before (OS-11 and 12) and after (OS-11A and 12A)
chemotherapy. All patients were treated with chemotherapy
including high dose of cisplatin and doxorubicin. All patients
had high-grade OS. Tumour material was processed directly after
biopsy. In brief, tumour pieces were washed in sterile phosphate-
buffered saline (PBS) and minced. Liver digest medium (Life
Technologies) was added during four consecutive 30-min incuba-
tions at 371C. Cells were collected, washed and cultured in DMEM-
F12 with 10% FCS, PS and 2.5mgml
 1 fungizone (Life techno-
logies) at 371C in a humidified, 5% carbon dioxide atmosphere.
Osteosarcoma morphology of all primary cell cultures was
confirmed by histological analysis. Primary cultures were used
until passage eight.
p53 reporter assay
To investigate phenotypic p53 status, primary OS cells were plated
at a density of 5 10
4 cells per well in a 24-wells plate. Cells were
transfected with either the p53-dependent reporter plasmid PG13-
Luc, or with the negative control construct MG15-Luc, as described
previously (van Beusechem et al, 2002). Relative luciferase
expression of PG13-Luc compared to MG15-Luc was used to
determine p53-status. Ratios of 0.5–2.0 were considered to
represent a p53-deficient status, ratios between 2 and 10 probably
represent a heterogeneous cell population consisting of p53-
deficient and wild-type cells, and ratios above 10 represent
functional p53 status.
Adenovirus and chemotherapeutic agents
The CRAd Ad5-D24RGD lacks 24 base pairs encoding eight amino
acids in the pRb-binding domain of E1A and carries a cyclic RGD
epitope in the HI-loop of the fibre (Suzuki et al, 2001). This CRAd
was propagated on A549 cells (American Type Culture Collection)
and purified using cesium chloride gradient banding and titrated
by end point limiting dilution on 293 cells (American Type Culture
Collection). Doxorubicin was purchased from Pharmacia &
Upjohn (Woerden, The Netherlands) and cisplatin from Pharma-
chemie BV (Haarlem, The Netherlands).
Cell viability assay
Cells were seeded in a 96-wells plate at a density of
5 10
3cellswell
 1 and incubated for 24h. Infections with a two-
fold dilution series of Ad5-D24RGD were performed in DMEM-F12
containing 2.5% FCS for 1h. Serial dilutions of chemotherapeutic
agents were added immediately, or after 24, 48 or 72h in medium
containing 10% FCS. Five to seven days poststart of treatment the
relative cell viability was measured by means of WST-1 conversion
assay (Roche Diagnostics, Mannheim, Germany). WST-1 conver-
sion was analysed by measuring the A450 using a Bio-Rad model
550 microplate reader (Hercules, CA, USA). Relative WST-1
conversion in treated cells compared to untreated cells was
calculated after subtraction of WST-1 conversion in the absence of
cells. For OS primary cells, differences in viability after treatment
with the best of either single agent compared to the combination
treatment were analysed using a two-sided Student’s t-test.
Combination effects in OS cell lines were assessed by a constant
ratio combination design in the range of 0.063 to 4-times the IC50
of the individual components. The mean combination index (CI)
was calculated from four data points at effective doses yielding 50,
75, 90 and 95% reduced viability, using the CalcuSyn program
(Biosoft, Ferguson, MO, USA). This program applies the combina-
tion-index equation described by Chou and Talalay (Chou and
Talalay, 1984). Combination index values below 0.9 were defined
as synergism; between 0.9 and 1.1 as additive; and above 1.1 as
antagonism. For simplicity, mutual exclusivity was assumed in
these combination experiments.
Quantitative PCR for adenoviral genomes
Cells were plated at a density of 5 10
3cellswell
 1 in a 96-wells
plate and infected with Ad5-D24RGD at a multiplicity of infection
(MOI) of 50 plaque-forming units (PFU) per cell. After 1h, a dose
of doxorubicin at approximately IC10 (drug concentration result-
ing in 10% inhibition in growth) was added. After 31h, cells were
harvested and lysed in PBS by three freeze/thaw cycles. Cleared
lysate (100ml) was treated overnight with 5mg proteinase K (Sigma,
St Louis, MO, USA) in a water bath at 371C. Quantitative PCR was
performed with a hexon-specific primer set: sense, 50-ATG ATG
CCG CAG TGG TCT TA-30, antisense, 50-GTC AAA GTA CGT GGA
AGC CAT-30 and the FastStart DNA Master SYBR Green I kit
(Roche Diagnostics, Mannheim, Germany) according to the
manufacturer’s protocol. The amount of viral DNA templates
was calculated on the basis of a standard curve generated by
amplification of a dilution series of the hexon gene containing
plasmid pBHG11 (Microbix biosystems, Toronto, Canada).
Cell growth assay
To determine the doubling time of OS cell cultures, cells were
plated at a density of 5 10
4cellswell
 1 in a six-wells plate. The
cells were cultured for up to 7 days and counted on days 1, 3, 5 and
7 using a Coulter Counter (Beckman Coulter, Fullerton, CA, USA).
The doubling time was calculated from three independent
experiments and is given as the average with standard deviation
(s.d.).
Cell cycle analysis
Cells were seeded at a density of 1.67 10
5 cells in a six-wells plate.
After 24h, cells were subjected to an IC10 or IC90 dose of
doxorubicin. At 31h or 6 days after adding doxorubicin, cells were
harvested and incubated in 300ml propidium iodide (PI) solution
(PBS supplemented with 0.05% PI, 0.1% Triton X-100, 0.1%
sodium citrate and 0.1% RNAse A; Sigma, St Louis, MO, USA) for
1h at 41C. A minimum of 7000 cells was analysed by flow
cytometry on a FACScan (Becton Dickinson, Erembodegem-Aalst,
Belgium) and subsequently by ModFitLT cell cycle analysis
software (Verity Software House, Topsham, ME, USA).
RESULTS
Combination of Ad5-D24RGD with cisplatin or
doxorubicin enhances the cytotoxic effect on OS cell lines
The combined effect of Ad5-D24RGD with cisplatin or doxorubicin
was studied on the OS cell lines SaOs-2, MG-63 and U2OS. First,
IC50 values for single treatment with cisplatin, doxorubicin or
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drug concentrations or CRAd MOI and measuring cell viability
6 days later (Table 1). Next, combination effects were studied
by simultaneous treatment in the range of 0.063 to 4-times the
individual IC50 (Figure 1A). Possible interactions between the
drugs and Ad5-D24RGD were determined by CalcuSyn analysis
(Figure 1B). The average CI values from three independent
experiments indicated that combined treatment with Ad5-
D24RGD and doxorubicin was synergistic in SaOs-2 and U2OS
cells (mean CI values 0.55 and 0.81, respectively) and additive in
MG-63 cells (mean CI¼1.07). Combination treatment with
cisplatin was on average synergistic in MG-63 and SaOs-2 cells,
with mean CI values of 0.77 and 0.46, respectively, and antagonistic
in U2OS cells (mean CI¼1.22). Owing to variation between
individual experiments, CI values sometimes extended into a
different classification, suggesting, for example, an antagonistic
effect of CRAd plus doxorubicin on MG-63 cells or an additive
effect of CRAd plus cisplatin on U2OS cells. However, combination
treatment was never less effective than either treatment alone.
Hence, in general, simultaneous treatment of OS cell lines with
Ad5-D24RGD and chemotherapy yielded additive to synergistic
effects.
Combination treatment of Ad5-D24RGD with cisplatin or
doxorubicin does not enhance the cytotoxic effect on OS
primary cell cultures
To verify if the combination treatments also resulted in
enhanced cytotoxicity on primary OS samples, we used a panel
of eight primary OS cell cultures (Table 2). All specimens were
diagnosed as high-grade OS. Five specimens were obtained from
patients that had not been subjected to chemotherapy; three
samples (marked A) were taken after chemotherapy. Functional
p53 status differed considerably, ranging from deficient to wild-
type activity. Marginal p53 activities in several samples
suggested heterogeneity. Interestingly, chemotherapy appeared
to select for more p53-deficient cell populations at least in one
of the two cases. Limited amounts of available primary cells
precluded CalcuSyn analysis over a range of CRAd and drug
concentrations. Therefore, cells were only treated with Ad5-
D24RGD, chemotherapeutic drug, or a combination of both at a
moderate toxic dose resulting in an estimated 20–60% cell kill.
In this range, combination effects on OS cell lines were most
evident (see Figure 1A). On different primary cell specimens, the
doses used ranged from 0.1 to 3PFUcell
 1 Ad5-D24RGD, 0.6 to
1mM doxorubicin and 3 to 18mM cisplatin. Surprisingly, and in
contrast to the observations made on OS cell lines, combination
treatment of Ad5-D24RGD with doxorubicin or cisplatin did in
most cases not result in a more pronounced cytotoxic effect
compared to the most effective single agent treatment (Figure 2).
Specimen OS-16 was the only exception where combination
treatment was significantly better than either single agent
treatment (Po0.05).
To investigate if combined treatment could be improved by
delayed addition of chemotherapeutic agents, primary OS cells
were infected with Ad5-D24RGD; and cisplatin or doxorubicin
were added 24, 48 or 72h later. As shown in Figure 3, this did also
not result in enhanced cell kill compared to monotherapy with
Ad5-D24RGD or cisplatin or doxorubicin.
Table 1 IC50 values of Ad5-D24RGD, doxorubicin and cisplatin on OS
cell lines
OS cell line
Ad5-D24RGD
(MOI
a)
Doxorubicin
(nM)
Cisplatin
(lM)
SaOs-2 8.573.3
b 37716 2.370.8
MG-63 15.777.3 34712 0.970.2
U2OS 1.171.2 2807190 5.673.0
aMOI¼multiplicity of infection; OS¼osteosarcoma.
bData are means with standard
deviation from at least three independent experiments.
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Figure 1 The oncolytic effect of Ad5-D24RGD in combination with doxorubicin or cisplatin on OS cell lines. Three OS cell lines (SaOs-2, MG-63 and
U2OS) were incubated at a concentration range of 0.063 to 4-times the average IC50 of each treatment agent. (A) Left panels represent cytotoxicity on OS
cell lines of Ad5-D24RGD (open diamonds), doxorubicin (open squares) as single agents or the combination of both (closed triangles). Right panels
represent cytotoxicity obtained with Ad5-D24RGD (open diamonds), cisplatin (open squares) or the combination (closed triangles). Cell survival was
expressed relative to nontreated controls. Data represent a typical experiment performed in triplicate. (B) Results from the combination experiments were
analysed by the CalcuSyn program. Data shown are mean CI values with s.d. from three independent experiments each performed in triplicate. CI values
below 0.9 were defined as synergistic, between 0.9 and 1.1 as additive and above 1.1 as antagonistic.
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random selection of the primary OS panel were subjected to
approximate IC10 (subtoxic) dose of cisplatin or doxorubicin
combined with an approximate IC70 (toxic) dose of Ad5-D24RGD
(Figure 4). On OS cell lines, a subtoxic dose of cisplatin or
doxorubicin did not reduce the Ad5-D24RGD cytotoxic effect. In
contrast, on most primary specimens the cytotoxic effect of Ad5-
D24RGD was inhibited by the low dose of cisplatin or doxorubicin.
Again, this significant antagonistic effect (Po0.05) was seen in all
primary OS cell cultures tested, except OS-16.
Combination with doxorubicin inhibits viral replication in
OS-11 and OS-12A cells, but not in OS-16, SaOs-2, MG-63
and U2OS cells
We postulated that the different outcome of the tested combina-
tion treatments might be due to a different effect of chemo-
therapeutic agents on viral replication. To test this hypothesis,
we measured viral replication in the presence or absence of
doxorubicin. This was performed on primary cell cultures OS-11
and OS-12A, where we had observed an adverse effect of
doxorubicin on Ad5-D24RGD-mediated cytotoxicity, and on
primary cell culture OS-16 and cell lines SaOs-2, MG-63 and
U2OS, where combination treatment had shown additive or
synergistic effects. Cells were infected with 50PFUcell
 1 Ad5-
D24RGD and one hour after infection cells were cultured in the
presence or absence of a subtoxic dose (IC10) of doxorubicin. The
next day, CRAd genome copy numbers were determined by
quantitative PCR analysis. As can be seen in Table 3, doxorubicin
decreased viral replication in OS-11 and OS-12A cells by 2.5- and
five-fold, respectively. In contrast, in OS-16, SaOs-2, MG-63 and
U2OS cells viral replication was not significantly affected. In fact,
viral replication in SaOs-2 cells was not even inhibited in the
presence of a toxic concentration of doxorubicin.
Doxorubicin increases the OS cell population in G2/M
phase of the cell cycle, but not in OS-11 and OS-12A cells
Towards explaining the different response of most primary OS
cultures vs OS-16 and OS cell lines, we investigated their cell
growth rate. SaOs-2, MG-63 and U2OS OS cell lines all exhibited a
fast proliferation rate with a population doubling time of 0.7–0.8
days (data not shown). In contrast, most primary OS specimens
proliferated much slower (doubling times ranging from 3.4 to 47
days; see Table 2). Osteosarcoma-16 cells were the exception, with
a doubling time of only 1.4 days. On the basis of this observation
and the known effect of doxorubicin in arresting cells in the G2
phase of the cell cycle, which has been reported to enhance viral
replication (Bernt et al, 2002), we investigated whether a G2 cell
cycle arrest occurred in OS cell lines and primary samples treated
with doxorubicin.
Within 31h, doxorubicin induced a G2 cell cycle arrest in SaOs-
2, MG-63 and U2OS cells (Figure 5). This was already evident when
cells were treated with an IC10 dose of doxorubicin and was more
pronounced at an approximately IC90 dose. In the same time,
doxorubicin also caused a marked increase in the proportion of
OS-16 cells in the G2/M phase of the cell cycle (Figure 6). In
contrast, the cell cycle status of OS-11 and OS-12A cells was hardly
affected. This was even the case after extended culture for 6 days,
that is, for more than one population doubling time (Figure 6). To
investigate if OS-11 and 12A cells would require higher doses of
doxorubicin to induce G2 arrest, cells were also treated with
doxorubicin at concentrations up to 1.5mM (approximate IC80).
Under these conditions, we observed even a decreased G2-phase
cell population in favour of the G1 cell cycle phase (data not
shown). Thus, an increased cytotoxic effect of combination
treatment of Ad5-D24RGD with doxorubicin on OS cells appeared
to correspond with susceptibility to doxorubicin-induced G2 cell
cycle arrest.
DISCUSSION
Combination treatment of chemotherapy and virotherapy holds
promise as a new strategy for cancer treatment (Khuri et al, 2000;
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Figure 2 The cytotoxic effect of Ad5-D24RGD with doxorubicin or
cisplatin on primary OS cell cultures. Eight primary OS cell cultures were
subjected to concentrations of Ad5-D24RGD (white bars), doxorubicin
(hatched bars; upper panel) or cisplatin (hatched bars; lower panel)
resulting in 20–60% cell kill or to a combination of CRAd plus
chemotherapeutic drug (black bars). Relative cell survival compared to
nontreated cultures was measured by WST-1 conversion assay. Data
shown are mean values with s.d. from experiments performed in triplicate.
Table 2 Characteristics of primary OS cells
Code Age M/F Diagnose p53 status
a (PG13-Luc/MG15-luc) Population doubling time (days)
OS-5A 7 F High grade OS 3.1 47
OS-6 25 M High grade OS 1.2 47
OS-8 6 M High grade OS 10.5 3.470.7
OS-11 16 F High grade OS 4.8 3.671.0
OS-11A 1.5 4.971.2
OS-12 13 F High grade OS 9.8 4.470.7
OS-12A 7.6 4.270.8
OS-16 15 F High grade OS 5.3 1.470.5
aFunctional p53 status was determined by measuring relative luciferase expression after PG13-Luc transfection compared to MG15-Luc transfection. Scores: ratio 0.5–2.0,
deficient; ratio 2–10, heterogeneous; and ratio410, functional. OS¼osteosarcoma.
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effect of the combination of Ad5-D24RGD with chemotherapy for
OS. In order to detect possible interactions between Ad5-D24RGD
and chemotherapeutic drugs, Ad5-D24RGD-infected OS cells were
cultured in the continuous presence of doxorubicin or cisplatin.
We found that OS cell lines are killed more effectively by a
combination of Ad5-D24RGD with doxorubicin or cisplatin than
by either single agent treatment. Combined effects were pre-
dominantly additive to synergistic. This is in line with observa-
tions reported by others on different cancer types (Heise et al,
1997, 2000; You et al, 2000; Li et al, 2001; Yu et al, 2001; Portella
et al, 2002). Surprisingly, however, combination treatment did not
lead to a similar more effective cell kill on primary OS cell cultures.
Only one of the eight tested primary OS cultures showed a
significantly increased cytotoxicity following combination treat-
ment. Delaying the addition of chemotherapeutic drug after virus
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Figure 4 Effect of subtoxic dose of doxorubicin or cisplatin on the
oncolytic effect of Ad5-D24RGD on OS cell lines and primary OS cells.
Osteosarcoma cell lines and primary OS cell cultures were treated with
approximate IC70 of Ad5-D24RGD (white bars) and the approximate IC10
of doxorubicin or cisplatin (hatched bars) or a combination (black bars).
Relative cell survival was measured by WST-1 conversion assay. Data
shown are mean values with s.d. from experiments performed in triplicate.
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Figure 3 Effect of delayed doxorubicin or cisplatin treatment after infection with Ad5-D24RGD on primary OS cell kill. Primary OS cells were infected
with Ad5-D24RGD and 24, 48 or 72h later cells were treated with doxorubicin or cisplatin (black bars). Controls treated only with virus or
chemotherapeutic drug are shown by white and hatched bars, respectively. Relative cell survival was measured by WST-1 conversion assay. Data shown are
mean values with s.d. from experiments performed in triplicate.
Table 3 Ad5-D24RGD viral replication in doxorubicin-treated OS cells
as determined by quantitative PCR analysis
OS cells
Genomes 10
5
 dox
a
genomes 10
5
+dox
+dox/
 dox
Average
ratio: +dox/
 dox (7s.d.)
5.8 3.5 0.6
OS-11 3.3 0.9 0.3 0.4 (70.2)
4.1 1.1 0.3
6.5 1.4 0.2
OS-12A 1 0.2 0.2 0.2 (70.04)
3.4 0.5 0.1
17 16 0.9
OS-16 8.9 14 1.6 1.3 (70.3)
75 94 1.3
2.1 2.9 1.4
SaOs-2 5.5 6.4 1.2 1.1 (70.3)
11 8 0.7
1.6 3.4 2.1
MG-63 7.7 7 0.9 1.2 (70.8)
11 6.2 0.6
20 15 0.8
U2OS 96 127 1.3 1.0 (70.3)
87 72 0.8
2.1 4.8 2.3
SaOs-2
b 5.5 5.1 0.9 1.8 (70.8)
11 25 2.3
aThe number of adenovirus genomes in cells cultured in the absence ( dox) or
presence (+dox) of a subtoxic dose doxorubicin was determined in three
independent experiments and the average ratio and s.d. was calculated.
bSaOs-2
cells treated with a toxic dose of doxorubicin. PCR¼polymerase chain reaction;
OS¼osteosarcoma.
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Figure 5 Effect of doxorubicin on cell cycle profile of OS cell lines. SaOs-2, MG-63 and U2OS cells were cultured for 31h in medium containing IC10 or
IC90 doxorubicin as indicated. DNA histograms were made by PI staining and FACS flow cytometry. DNA histograms were analysed by ModFitLT cell cycle
analysis software. Percent cells in G2/M phase of the cell cycle are indicated in the panels.
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Figure 6 Effect of doxorubicin on cell cycle profile of primary OS cells. Osteosarcoma-11, OS-12A and OS-16 cells were cultured in medium containing
IC10 doxorubicin for 31h or 6 days as indicated. DNA histograms were made and analysed as described in the legend to Figure 5.
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sinfection for up to three days did not improve cell killing. This
suggested that the inhibitory effect of chemotherapy on virother-
apy in primary cells was unrelated to interference with early steps
of virus infection.
Our findings raise the question why OS cell lines and primary
cells responded differently to combination treatment. To answer
this question we need insight into the mechanism of synergy
between chemotherapy and virotherapy. Two different, not
mutually exclusive mechanisms have been proposed to explain
combination effects of CRAds and chemotherapy. On one hand, it
has been postulated that CRAds enhance the efficacy of
chemotherapy through viral E1A expression rendering tumour
cells more susceptible to DNA damaging agents (Sanchez-Prieto
et al, 1996). On the other hand, it was reported that adenoviral
replication is increased in the G2 phase of the cell cycle
(Steinwaerder et al, 2000; Bernt et al, 2002). Chemotherapeutic
agents that induce a G2/M cell cycle arrest were shown to enhance
viral replication, whereas an induction of a G1 cell cycle arrest
poorly supported viral replication (Bernt et al, 2002). In our study,
enhanced efficacy of the Ad5-D24RGD CRAd in combination with
chemotherapy appeared to correlate with susceptibility to chemo-
therapy-induced G2 cell cycle arrest, supporting at least the second
explanation for synergy between CRAd-induced oncolysis and
chemotherapy. This suggests that differential susceptibility of OS
cell lines and primary samples to doxorubicin or cisplatin could
have dictated a different response to combination treatment.
Differential susceptibility of cell lines and primary samples to
chemotherapy is not uncommon. For example, the activity of
topotecan, irinotecan and SN-38 against cancer cell lines was
shown to differ from their activity against corresponding primary
samples (Jonsson et al, 2000). As chemotherapy-induced G2 cell
cycle arrest is more likely to occur in fast than in slowly dividing
cells and OS cell lines had a much higher cell division rate than
primary OS cells, the former cells may be more susceptible to G2
cell cycle arrest and thereby to enhancement of CRAd efficacy by
chemotherapy. In line with this reasoning, the only primary
sample that was susceptible to combination treatment (OS-16)
proliferated markedly faster than any of the other primary cell
cultures. However, slowly dividing primary cell cultures did also
not arrest in G2 phase when exposure to doxorubicin was
prolonged to encompass more than a population doubling time.
Moreover, while resistance to chemotherapy due to low cell
division rate may explain a lack of synergy in primary OS cells, it
does not explain why chemotherapy even counteracted virotherapy
in many samples. Our findings suggest a delicate balance between,
on one hand, a favourable role of chemotherapy-induced G2 cell
cycle arrest on viral replication and, on the other hand, a so far
unresolved adverse effect of chemotherapy on CRAd replication in
the absence of G2 cell cycle arrest.
The markedly different response of OS cell lines and primary OS
specimens to combination treatment also raises the question which
of these cells are more relevant to predict efficacy of combination
treatment in the clinic. Although direct comparative data are not
available, we regard our findings obtained on primary specimens
as more relevant predictors for clinical outcome than the
observations made on cell lines. This is based on the fact that
the cytotoxic effects of doxorubicin and cisplatin on primary
tumour cultures were already shown to correlate well with results
gathered in phase II clinical trials (Fridborg et al, 1999).
Furthermore, it is known that the vast majority of human tumour
cells in vivo are in a quiescent rather than in a fast proliferating
state (Weisenthal, 1991, pp 103–147). In this respect, the slow in
vitro growth rate for primary OS cells found herein is more
comparable with the reported growth rate for OS cells in vivo than
that of the tested OS cell lines (Band and Kocandrle, 1975). This
makes our observation that combination treatment was not
successful against slowly dividing OS cells particularly relevant.
Our observations described herein should not be interpreted as a
discouragement for combination treatments with CRAds and
chemotherapeutic agents altogether. It should be emphasised that
Ad5-D24RGD killed primary OS cells very efficiently and that this
CRAd did not hamper the effect of the applied chemotherapy
against primary OS cells. Hence, treating OS patients with CRAds in
the course of continued chemotherapy is not expected to affect the
standard treatment. However, chemotherapy did reduce the efficacy
of CRAd treatment. Therefore, we propose that if combination
treatment of OS with CRAds and chemotherapy is considered, the
virotherapy and chemotherapy agents should best be administered
in intermittent administration schemes. Finally, in general, our
findings underscore the importance of preclinical testing of new
genetic anticancer agents and treatment regimens on primary
human cancer specimens, because as shown herein the outcome
can be entirely different from results obtained on cell lines.
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